Management of acute stroke in patients taking novel oral anticoagulants

• Each year, 1 center dot 0-2 center dot 0% of individuals with atrial fibrillation and 0 center dot 1-0 center dot 2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0 center dot 2-0 center dot 5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or hemorrhagic stroke. Specifically, we discuss the role of thrombolysis in anticoagulated patients with acute ischemic stroke and factors to consider concerning restarting anticoagulation after acute ischemic and hemorrhagic stroke.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

acute stroke

anticoagulants

intracerebral hemorrhage

secondary

prevention

thrombolytic therapy

Publikations- och innehållstyp

for (ämneskategori)

ref (ämneskategori)